Compare CDT & NXTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDT | NXTS |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | Israel |
| Employees | 6 | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 4.3M |
| IPO Year | N/A | N/A |
| Metric | CDT | NXTS |
|---|---|---|
| Price | $1.98 | $5.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 57.7K | 24.1K |
| Earning Date | 04-15-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $0.55 |
| 52 Week High | $11.00 | $6.21 |
| Indicator | CDT | NXTS |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 60.28 |
| Support Level | $1.54 | $0.66 |
| Resistance Level | $2.30 | $5.31 |
| Average True Range (ATR) | 0.23 | 0.61 |
| MACD | -0.16 | -0.09 |
| Stochastic Oscillator | 1.83 | 38.44 |
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. The company has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The group is committed to creating shareholder value through licensing, strategic M&A, and positioning the company as a platform for transformative innovation.
Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.